恆泰艾普(300157.SZ):碩晟科技、李麗萍合計持有7139萬股 成為公司持股10%以上股東
格隆匯 8 月 20日丨恆泰艾普(300157.SZ)公佈,公司於2020年8月19日收到北京碩晟科技信息諮詢有限公司編制的《簡式權益變動報告書》。
2020年8月18日,李麗萍通過證券交易所集中交易增持恆泰艾普50萬股股份,增持後碩晟科技、李麗萍合計持有上市公司7139.1243萬股股份,占上市公司總股本10.03%。
截至2020年8月18日,信息披露義務人及其一致行動人通過二級市場集中競價方式持有上市公司7139.1243萬股份,占上市公司總股本的10.03%,成為公司持股10%以上股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.